

# Clinical Site Details (IRB222815)

## Protocol Information

### Question 1

Are you submitting this protocol for the first time?

Answer

Yes

### Question 2

Has this study been disapproved or withdrawn from another IRB?

Answer

N/A

N/A

### Question 3

Are you transferring oversight from another IRB?

Answer

N/A

N/A

### Question 4

Title of Protocol

Answer

test

### Question 5

Protocol Number

Answer

test

### Question 6

Study Duration

Answer

test

## Question 7

Sponsor

**Answer**

test

## Question 8

Funding Source

**Answer**

Industry

**No Documents Uploaded**

## **Investigator Information**

### **Question 1**

Investigator Name

**Answer**

test

### **Question 2**

Investigator Email

**Answer**

test

### **Question 3**

Sub Investigator Name

**Answer**

test

### **Question 4**

Sub Investigator Email

**Answer**

test

### **Question 5**

Primary point of contact if different from above

**Answer**

test

### **Question 6**

Primary point of contact email address

**Answer**

test

### **Question 7**

Has the investigator ever had an FDA audit?

**Answer**

No  
N/A

## Question 8

How long has the investigator been involved in research?

**Answer**

1-5 years

## Question 9

What is the investigator's NPI if applicable

**Answer**

test

**What training in the field of human subjects protection has the investigator completed?**

☒ OHRP Human Subject Assurance Training

**Explanation**

test

☒ CITI Program Training

**Explanation**

test

☐ Certified Physician Investigator Training

**Explanation**

test

☐ ACRP training (CCRC, CCRA)

**Explanation**

test

☐ SOCRA (CCRP)

**Explanation**

test

☐ Graduate or undergraduate research studies or degrees

**Explanation**

test

☐ Academy of Physicians in Clinical Research

**Explanation**

test

☒ Other

**Explanation**

test

**Question 11**

What is the current number of research studies supervised by the investigator?

**Answer**

test

**Question 12**

Do you have any pending or active restrictions related to research or the practice of medicine?

**Answer**

Yes

**Explanation**

test

**Question 13**

Does your site have an FWA?

**Answer**

No

**Question 14**

Please provide FWA number

**Answer**

N/A

**No Documents Uploaded**

**No Documents Uploaded**

**No Documents Uploaded**

## Study Information

### Question 1

What type of research is being conducted?

#### Answer

Device

N/A

**No Documents Uploaded**

## Informed Consent Form

**What type of consent is required for this study?**

☒ No consent (requesting waiver of consent)

**Explanation**

gedg

☒ undefined

**Explanation**

gedg

☐ Written, signed consent by subject

**Explanation**

gedg

☒ Written, signed consent by legally authorized representative

**Explanation**

gedg

☐ Written, signed assent by minor

**Explanation**

gedg

☐ HIPAA authorization agreement

**Explanation**

gedg

☐ Waiver of HIPAA agreement

**Explanation**

gedg

☐ Online/website/electronic signature consent

**Explanation**

gedg

## Question 2

Will HIPAA authorization language be included in the ICF (informed consent form)?

**Answer**

N/A

### Question 3

Will the participants be compensated for participation in the study?

**Answer**

Yes

### Question 4

Will the consent forms be offered in languages other than English?

**Answer**

No

### Question 5

Have the document been translated by a professional translator?

**Answer**

N/A

N/A

### No Documents Uploaded

The informed consent process is a continuous process and the IRB expects that proper subject consent is ensured by the investigator throughout the research study. To comply with the terms set forth by this IRB, the investigator must ensure that:

- No study procedures shall be conducted prior to completion of the informed consent forms which include subject or legally authorized representative (LAR) signatures and date, investigator or person obtaining consent signature and date, and providing a copy of the signed consent to the study participant.
- The identified research participant is given plenty of time to consider their participation in the study and all questions are answered. The identified research participant must be told that their participation in the study is voluntary and that they are under no obligation to participate. The potential participant must voice understanding before proceeding.
- The consent discussion must be in language understandable to the potential research participant's comprehension level.
- The informed consent discussion must be performed in a private setting free from other people who may overhear the discussion, such as a private exam room or other closed-door setting.
- Only the most current, IRB-approved consent forms may be used for enrollment.
- All efforts must be taken to ensure participant anonymity including:
  - Safe storage of subject identifiers-all subject identifiers must be coded and de-identified
  - Safe storage of subject identifiers-all subject identifiers must be coded and de-identified
  - All paper-based records will be stored in a double-locked area such as a locking filing cabinet inside of a locking door and only accessible to authorized staff.
  - All electronic-based records will only be accessed by authorized staff using secure login credentials.

☐ Your initials below signify that you have read the terms and agree with them:



## Protocol Procedures

### Which subject populations will be enrolled in the study?

☐ Adults

N/A

☐ Children (17 years and under)

N/A

☐ Blind/Visually Impaired

N/A

☐ Deaf/Hard of Hearing (including sign language communicators)

N/A

☐ Individuals with impaired decision-making (requiring a LAR, including those with impaired or diminished mental capacity, dementia, and those suffering from mental health disorders)

N/A

☐ Educationally Disadvantaged/Impaired or no reading skills

N/A

☐ Economically disadvantaged

N/A

☐ Healthy individuals

N/A

☐ Terminally ill individuals

N/A

☐ HIV positive

N/A

☐ Hospitalized

N/A

☐ Institutionalized (including nursing home, LTAC, assisted living, residential facility, mental hospital)

N/A

☐ Prisoners

N/A

☐ Military Personnel

N/A

☐ Pregnant women

N/A

☐ Human fetuses/neonates

N/A

☐ Non-English speakers

N/A

☐ Women only

N/A

☐ Men only

N/A

☐ Other

N/A

### Which race and ethnic groups will be enrolled in the study?

☐ White, not of Hispanic origin

N/A

☐ White, of Hispanic origin

N/A

☐ Black, not of Hispanic origin

N/A

☐ Black, of Hispanic origin

N/A

☐ American Indian/Alaskan Native

N/A

☐ Asian

N/A

☐ Native Hawaiian/Pacific Islander

N/A

☐ Multiracial

N/A

☐ Other

N/A

### Question 1

Will any subject populations be excluded from the study?

**Answer**

N/A

N/A

### Question 2

How many subjects will be enrolled in the study?

**Answer**

N/A

**What recruitment methods will be used in the study?**

☐ In-person conversation during routine office visits

N/A

☐ Recruiting participants from previous research studies

N/A

☐ Mass print advertisements such as a newspaper, magazine, or billboard

N/A

☐ Flyer, poster, or bulletin board in office

N/A

☐ Radio or television ads

N/A

☐ Direct mail to potential subjects

N/A

☐ Internet including social media recruiting

N/A

☐ Chart review

N/A

☐ Telephone screening

N/A

☐ Other

N/A

### Question 3

What is the location(s) name and address where the research procedures will take place?

**Answer**

N/A

#### **Question 4**

Will any samples or data collected in this study be retained for future research?

#### **Answer**

N/A

Please explain how the data and/or samples will be stored, secured, and de-identified. Include information on how the data and/or samples might be used for future research \*

N/A

#### **No Documents Uploaded**

☐ Your initials below signify that you have read the terms and agree with them:

## Submission Form

By submitting this application you attest to the following:

- Research will not commence prior to receiving the IRB approval letter.
- The principal investigator will personally supervise and/or conduct the study.
- The principal investigator ensures that all persons involved in conducting the study are trained and have proper credentialing for conducting research.
- Only the most current IRB-approved consent form will be used to enroll subjects.
- No changes will be made to the research protocol, consents forms, and all patient-facing materials without the approval of the IRB
- The study procedures will comply with all applicable laws and regulations regarding the conduct of research
- All findings from the study that directly affect subject safety will be communicated to subjects and to this IRB
- All serious adverse events (SAEs), whether related to the study procedures or not, will be reported to this IRB within 2 business days of the investigator becoming aware of the event for IRB safety review
- The sponsor agrees to submit and provide payment to this IRB for annual review yearly

☐ Your initials below signify that you have read and agree to the terms listed above